email article
Scores with the 22-gene Decipher genomic classifier (GC) were independently associated with risk for metastasis, prostate cancer-specific mortality, and overall survival among men with recurrent prostate cancer treated with salvage radiotherapy with or without bicalutamide.
These results suggest that not all men with biochemically recurrent disease after surgery will benefit from hormone therapy, reported Felix Y. Feng, MD, of the University of California San Francisco, and colleagues in
Using specimens from the phase III NRG/RTOG9601 clinical trial, Feng and colleagues generated GC scores from 352 patients with median follow-up of 13 years. Patient GC scores were calculated on a continuous scale from 0 (lowest) to 1 (highest). Scores were then classified as low (42%), intermediate (38%), or high (20%) using previously established 0.45 and 0.60 as cutoffs.
MD Anderson and Mirati Therapeutics collaborate to expand evaluation of potent KRAS inhibitors
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati s two investigational small molecules, potent and selective KRAS inhibitors - adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents - which target two of the most frequent KRAS mutations in cancer.
The collaboration will combine MD Anderson s clinical trial infrastructure and expertise with Mirati s differentiated targeted oncology pipeline. Under the terms of the agreement, collaborative preclinical and clinical studies will be conducted in several solid tumors, including non-small cell lung, pancreatic, colorectal and gynecological cancers over the five-year period of the collaboration.
Date Time
MD Anderson and Mirati Therapeutics announce KRAS strategic research and development collaboration in solid tumors
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.
The collaboration will combine MD Anderson’s clinical trial infrastructure and expertise with Mirati’s differentiated targeted oncology pipeline. Under the terms of the agreement, collaborative preclinical and clinical studies will be conducted in several solid tumors, including non-small cell lung, pancreatic, colorectal and gynecological cancers over the fi
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. for BAVENCIO® (avelumab) .